Therapeutic Innovation in cerebrovascular disease

Within the unit 825, Isabelle Loubinoux’team has been dealing with with stroke disease since 15 years. Her team (3) was created by Inserm CSS3 in 2011.

We have a close collaboration with the neurological department (F. Chollet, J-F Albucher, N Raposo, J. Pariente (team 2), the rehabilitation department (Pr Roques, P. Marque, X de Boissezon, E Castel-Lacanal) and the Center of Clinical Investigation (O. Rascol, C. Thalamas).

We have access to heavy equipment: a 3T MRI entirely devoted to research, research sessions made available at the PET Centre of the university hospital, primate animal housing and, in 2 years, a renovated small-animal house equipped with suitable imaging tools (7T MRI and micro-PET). The technical facilities also include stereotactic transcranial magnetic stimulation.

Scientific objective

The main objectives of the ongoing project are on the one hand to develop and adapt advanced neuroimaging techniques to translational and clinical research, and, on the other hand, to couple these neuroimaging techniques to brain stimulation techniques in patients and controls for a better understanding of the pathophysiological mechanisms of the neurological disorders or handicaps, so as to improve their early diagnosis and to define adapted therapeutic or rehabilitative approaches.

Our project needs to determine experimentally the therapeutical strategies that will have a major clinical impact on future clinical treatments for stroke specifically in highly invalidated patients. Hemiplegia is the more common deficit. First cause of handicap, stroke has a heavy economical cost. Our main result is that ipsilesional activity must be promoted. Non invasive stimulation focused on this cerebral cortex show a cettain efficacy on motor recovery. Its modalities must be dertermined before being applied to the clinic. Vitual reality could help recovery of patients at home. Today, no pharmacological treatment has been validated in human clinical when deficits are constituted.

We demonstrated that Prozac significantly augments the ratio of independent patients. Other hopes rely on cerebral bioprosthesis (celular therapy combined with biomaterials).            

Expected health effects

Our aim is to develop methods of neuroimaging for clinical research and, as far as possible, for clinical practice, since imaging and quantitative analysis of images are a key-point of development of a clinical care based on evidence, and on suited and minimally invasive care adapted to individuals. The different strategies tested would allow to propose new therapeutic strategies of care.

Key words

Stroke, MRI imaging, PET, TMS, rehabilitation, stem cells, implant, nanotechnologies

Research training

M2R Neuropsychology and Clinical Neurosciences

M2R Neuroscience, Behaviour and Cognition

Cooperation and Partnerships

  • LAAS, CIRIMAT, Ecole Vétérinaire de Toulouse et Sanofi-Aventis
  • Fédération de Neurologie, Hôpital Purpan
  • Service de Médecine-Physique et Réadaptation, Pr Roques, Hôpital Rangueil
  • CerCo (Centre de Recherche Cerveau et Cognition)
  • Collaboration avec l’IRIT (Institut de Recherche en Informatique de Toulouse ; B. Pavard)
  • Collaboration avec Leonardo G. Cohen, directeur du Laboratoire Human Cortical Physiology Section and Stroke Neurorehabilitation Clinic » au sein du NINDS/NIH (National Institute of Neurological Disorders and Stroke NIH)
  • Collaboration avec le LAPMA (Bernard Thon)